Carfilzomib

2:28
Game-changing drug classes for multiple myeloma
Gareth Morgan
2:07
ASPIRE update: promising results for MM
Alberto Rocci
9:59
Myeloma 2017 day 2 highlights: MRD, targeted therapies and imaging advances
Gareth Morgan et al.
2:42
The IFM 2012-03 trial: what will the next step be?
Xavier Leleu
0:45
Key findings of the Endeavour study
Evangelos Terpos
5:23
The risk of skeletal adverse events with zoledronic acid
Heinz Ludwig
1:07
Lenalidomide maintenance – an active approach to treating MM?
Gareth Morgan
1:37
Which is the best combination therapy in relapsed and refractory multiple myeloma?
Meletios Dimopoulos
3:07
Comparing continuous and fixed duration myeloma treatment with triplets and doublets
Evangelos Terpos
4:08
How can plasma cell leukemia be managed?
Saad Usmani
5:42
Phase III study shows carfilzomib is an effective addition to standard myeloma therapy
Andrew Stewart
1:39
Phase III ASPIRE study of carfilzomib, lenalidomide and dexamethasone in relapsed myeloma
Jeffery Matous
3:16
Phase III ASPIRE study and prospective anti-CD38 therapy for myeloma
Keith Stewart
5:04
Recent investigational advances in the management of relapsed/refractory myeloma
Paul Richardson
3:48
KEYNOTE-183 trial of pembrolizumab in multiple myeloma: trial design and rationale
Jatin Shah
23:19
12th International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2014: Day 2 meeting highlights
Anton Hagenbeek et al.
VJHemOnc VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

VJHO needs the contact information you provide to inform you about our latest hemonc news and videos, educational courses and industry supported content (some of which may be promotional in nature). You may unsubscribe from these communications at anytime. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy.

The content of VJHemOnc is intended for healthcare professionals